Marketing authorisation recommended for Susvimo (ranibizumab) for neovascular age-related macular degeneration

EMA has recommended granting a marketing authorisation in the European Union for Susvimo (ranibizumab) to treat adults with neovascular (wet) age-related macular degeneration (nAMD). It is for use only in combination with a refillable implant surgically inserted into the eye in people whose disease is stable after responding to intravitreal treatment with a vascular endothelial growth factor (VEGF) inhibitor medicine. AMD is a chronic, progressive disease of the macula and a leading cause of central vision loss among people over the age of 50 years. nAMD is a form of advanced AMD that, if left untreated, causes rapid and severe loss of vision and remains a leading cause of visual impairment in the older population.